Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

CD19, a B-cell surface protein ... antibody affinity measurement and detection of anti-CD19 CAR expression. The high activity of such proteins has been confirmed by ELISA, SPR and flow cytometry ...

“In line with our goal of becoming a more focused and streamlined organization, we are optimizing our CD19 CAR-T portfolio ... into additional aggressive B-cell malignancies, including Richter ...

The high-affinity CD19 proteins from ACROBiosystems exhibit the potential to effectively detect the anti-CD19 CAR expression on the surface of transduced T cells. These proteins have been ...

Of note, unlike other CAR T-cell therapies, the CD19-directed genetically modified ... have relapsed or refractory ALL after ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...